Egyptian evidence-based consensus on clinical practice recommendations for the management of familial Mediterranean fever

Egyptian Rheumatology and Rehabilitation

Table 4 The treatment target in FMF management

Treatment target		LE	GoR	Mean Rate±SD	% of agreement	Level of agreement
Clinical target	• Complete response: ≤ 1 FMF attack in 6 months • The alternate target is nearly a complete response: one attack in 3 months	4	C	8.09±1.41	85.7%	H
Laboratory response	Serum amyloid A (SAA) < 10 mg/L
Functional response	Patient-Reported Outcomes Measure (PROMs): functional ability (CHAQ/HAQ), and quality of life assessment A minimum clinically important difference (MCID) of 0.22 is used to consider functional outcome improvement

LE level of evidence, GoR Grade of Recommendation, FMF familial Mediterranean fever, CHAQ Child Health Assessment Questionnaire, SAA serum amyloid A, MCID minimum clinically important difference, PROMs Patient-Reported Outcomes Measure